TY - JOUR
T1 - Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments
AU - McCraw, Alex J.
AU - Chauhan, Jitesh
AU - Bax, Heather J.
AU - Stavraka, Chara
AU - Osborn, Gabriel
AU - Grandits, Melanie
AU - López-Abente, Jacobo
AU - Josephs, Debra H.
AU - Spicer, James
AU - Wagner, Gerd K.
AU - Karagiannis, Sophia N.
AU - Chenoweth, Alicia
AU - Crescioli, Silvia
PY - 2021/9/4
Y1 - 2021/9/4
N2 - IgE, the predominant antibody class of the allergic response, is known for its roles in protecting against parasites; however, a growing body of evidence indicates a significant role for IgE and its associated effector cells in tumour immunosurveillance, highlighted by the field of AllergoOncology and the successes of the first-in-class IgE cancer therapeutic MOv18. Supporting this concept, substantial epidemiological data ascribe potential roles for IgE, allergy, and atopy in protecting against specific tumour types, with a corresponding increased cancer risk associated with IgE immunodeficiency. Here, we consider how epidemiological data in combination with functional data reveals a complex interplay of IgE and allergy with cancer, which cannot be explained solely by one of the existing conventional hypotheses. We furthermore discuss how, in turn, such data may be used to inform future therapeutic approaches, including the clinical management of different patient groups. With epidemiological findings highlighting several high-risk cancer types protected against by high IgE levels, it is possible that use of IgE-based therapeutics for a range of malignant indications may offer efficacy to complement that of established IgG-class antibodies.
AB - IgE, the predominant antibody class of the allergic response, is known for its roles in protecting against parasites; however, a growing body of evidence indicates a significant role for IgE and its associated effector cells in tumour immunosurveillance, highlighted by the field of AllergoOncology and the successes of the first-in-class IgE cancer therapeutic MOv18. Supporting this concept, substantial epidemiological data ascribe potential roles for IgE, allergy, and atopy in protecting against specific tumour types, with a corresponding increased cancer risk associated with IgE immunodeficiency. Here, we consider how epidemiological data in combination with functional data reveals a complex interplay of IgE and allergy with cancer, which cannot be explained solely by one of the existing conventional hypotheses. We furthermore discuss how, in turn, such data may be used to inform future therapeutic approaches, including the clinical management of different patient groups. With epidemiological findings highlighting several high-risk cancer types protected against by high IgE levels, it is possible that use of IgE-based therapeutics for a range of malignant indications may offer efficacy to complement that of established IgG-class antibodies.
KW - IgE
KW - antibodies
KW - cancer
KW - immunotherapy
KW - AllergoOncology
U2 - 10.3390/cancers13174460
DO - 10.3390/cancers13174460
M3 - Review article
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 17
M1 - 4460
ER -